XL

Xlife Sciences AGSWX Xlife Stock Report

Last reporting period 31 Dec, 2023

Updated 18 Sep, 2024

Last price

Market cap $B

0.265

Micro

Exchange

XSWX - Six Swiss Exchange

XLS.SW Stock Analysis

XL

Uncovered

Xlife Sciences AG is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

33/100

Low score

Market cap $B

0.265

Dividend yield

Shares outstanding

5.199 B

Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company is headquartered in Zurich, Zuerich and currently employs 19 full-time employees. The company went IPO on 2019-09-30. The firm focuses on investing in technologies in the life science industry. The company supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The firm offers its investors direct access to the further development of technologies at a very early stage. The firm cooperates with industrial partners and universities.

View Section: Eyestock Rating